Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small-molecule injectable drugs for the treatment of cancer. The Company has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinsonâ€™s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	19M 16.69M 15.38M 14.38M 26.97M 1.79B 27.46M 185M 71.47M 884M 71.36M 69.8M 3.07B	P/E 2024	-3.13x	P/E 2025	0.13x
Enterprise Value	32.83M 28.83M 26.57M 24.84M 46.59M 3.1B 47.44M 319M 123M 1.53B 123M 121M 5.31B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	51.55%	Yield 2024 *	-	Yield 2025	-

06-18	Oncotelic Therapeutics, Inc. Launches AI-Powered GMP Manufacturing Services Platform At BIO International Convention 2026	CI
06-17	Oncotelic Therapeutics, Inc. And TechForce Robotics, Inc. Advance AI-Powered GMP Manufacturing Services Platform For Revenue-Generating AI And Robotics Manufacturing Services	CI
06-17	TechForce Robotics Advances Phase 2 Deployment Of PUR-E Autonomous Clean Room Support Robot At SAPU Bio OEB-5 Sterile Injectable cGMP Facility	CI
06-08	Oncotelic Therapeutics, Inc. Showcases Pdaoai Capability in Advancing Drug Development	CI
05-14	Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Sapu Nano And Oncotelic Therapeutics, Inc. Announce First Patient Dosed In Phase 1b Trial Of Sapu003, An Intravenous Deciparticle Formulation Of Everolimus	CI
04-30	Oncotelic Therapeutics Advances Toward Commercial Launch of Ai-Enabled Robotics Platform	CI
04-15	Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Oncotelic Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-06	Nightfood Holdings, Inc. and Oncotelic Therapeutics, Inc. Execute Joint Development, Manufacturing, and Licensing Agreement	CI
04-02	Oncotelic Therapeutics And TechForce Robotics Enter Strategic Partnership To Commercialize PDAOAI-Enhanced GMP Robotics Platform	CI
03-24	Oncotelic Therapeutics, Inc.'s Sapu Nano Launches Deciparticle Platform and Presents Clinical Pipeline	CI
02-12	Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International Ip Coverage for Ot-101, Strengthening Cns and Neurology Commercialization Pathway	CI

06-18	Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026	AQ
06-17	Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services	AQ
06-08	Oncotelic Showcases PDAOAI™ Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 Keynote	AQ
06-05	NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies	AQ
06-05	Oncotelic Therapeutics Inc. Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies	AQ

Manager	Title	Age	Since
Vuong Trieu CEO	Chief Executive Officer	61	2019-04-21
Amit Bhupendra Shah DFI	Director of Finance/CFO	59	2019-06-30
Seymour H. Fein CTO	Chief Tech/Sci/R&D Officer	77	2020-01-05

Director	Title	Age	Since
Vuong Trieu CHM	Chairman	61	2019-04-21
Steven King BRD	Director/Board Member	61	2020-05-10
Anthony Maida BRD	Director/Board Member	61	2020-05-10

Mateon Therapeutics, Inc. Stock Other OTC

Stocks

MATN

US57667K1097

Biotechnology & Medical Research

Valuation: Mateon Therapeutics, Inc.

Latest news : Mateon Therapeutics, Inc.

Press Releases: Mateon Therapeutics, Inc.

Managers and Directors: Mateon Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATEON THERAPEUTICS, INC.	-.--%	-.--%	-	-	19M
ARGENX SE	+0.26%	+1.03%	+63.49%	+118.38%	55.35B
WUXI APPTEC CO., LTD.	+1.58%	+14.12%	+72.87%	+85.18%	51.92B
BIONTECH SE	-1.46%	-0.98%	-14.12%	-16.00%	22.76B
INSMED INCORPORATED	+0.99%	+9.05%	-0.36%	+423.40%	22.64B
WUXI BIOLOGICS (CAYMAN) INC.	-0.18%	+7.48%	+32.16%	-14.07%	17.36B
GENMAB A/S	-3.76%	+1.47%	+25.56%	-36.11%	16.1B
PHARMAESSENTIA CORPORATION	+3.02%	+12.74%	+143.33%	+308.04%	13.96B
EXELIXIS, INC.	-0.23%	+2.54%	+22.28%	+168.03%	13.38B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.31%	+6.52%	+28.62%	-	12.27B
Average	+0.27%	+5.82%	+41.53%	+129.61%	25.08B
Weighted average by Cap.	+0.37%	+6.54%	+46.90%	+121.43%

	2024	2025
Net sales	-	-
Net income	-4.52M -3.97M -3.66M -3.42M -6.42M -427M -6.54M -43.93M -17.01M -210M -16.99M -16.62M -731M	249M 219M 202M 189M 354M 23.52B 360M 2.42B 938M 11.6B 936M 916M 40.3B
Net Debt	13M 11.42M 10.52M 9.84M 18.45M 1.23B 18.79M 126M 48.9M 605M 48.83M 47.76M 2.1B	13.82M 12.14M 11.19M 10.46M 19.62M 1.3B 19.98M 134M 51.99M 643M 51.91M 50.77M 2.23B